In the field of advanced IBD therapies, significant progress has been made in recent years. The long-established class of anti-TNF agents has been complemented by additional therapeutic options, including anti-interleukins, anti-integrins, S1P modulators, and JAK inhibitors.
The overview presents key information for each therapy, including the drug class, target molecule, active ingredient, trade name, marketing authorization holder, regulatory approval, form of administration and dosage, as well as contraindications.
You can download the overview here